Dr. David Ho was one of the first scientists to propose that AIDS was caused by a virus, and was first to promote a cocktail of protease inhibitors and antiretroviral therapy for AIDS patients. For this work he received the 1996 Man of the Year award from TIME magazine. He is a Taiwanese-American.

Genentech Inc, a US biotechnology research company, plans to found a research joint venture with the Taiwanese government in Hsinchu to develop AIDS treatments headed by Taiwanese-American researcher David Ho (何大一), Chinese-language news-papers said yesterday.

Ho has reportedly agreed to serve as chairman of the planned joint-venture — to be known as TaiMed — which is to be set up in Hsinchu Biochemical Science Park (新竹生醫科學園區), reports quoted Liang Chi-ming (梁啟銘), director of the Office of Public Affairs at the Academia Sinica, as saying.

Academia Sinica is the nation’s top research institute.

South San Francisco-based Genentech will transfer its CD4 antibody technology to TaiMed, the United Daily News said, citing Liang.

CD4, which exists on the membrane of T cells, is a primary receptor used by HIV-1 to gain entry into host T cells, which plays an essential role in cell-mediated immunity and targets of HIV infection. If developed successfully, the CD4 antibody will block CD4 from destroying the immune system.

New CD4 treatment for HIV being explored in Taiwan
Tagged on:             

Leave a Reply

Your email address will not be published. Required fields are marked *